CD276 Antibody Market By Type (Monoclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies); By Application (Oncology, Immuno-Oncology Research); By End User (Biopharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

CD276 Antibody Market: B7-H3 ADCs Move Closer to Commercial Oncology

The Global CD276 Antibody Market is valued at USD 450 million in 2025 and is projected to reach USD 1.26 billion by 2032, expanding at a strong CAGR of 15.8%. The forecast represents an absolute revenue increase of USD 810 million, with the market reaching about 2.8 times its 2025 size by 2032.

 

The CD276 antibody market, also known as the B7-H3 antibody market, is developing across two commercially different product groups. Research-use antibodies already generate recurring demand from pharmaceutical and biotechnology companies, academic institutes, contract research organizations, diagnostic laboratories, and translational oncology teams. The larger future revenue opportunity is linked to therapeutic products, particularly antibody-drug conjugates, or ADCs, being developed for small cell lung cancer, nasopharyngeal carcinoma, prostate cancer, esophageal cancer, osteosarcoma, glioblastoma, neuroblastoma, and other solid tumors.

 

The therapeutic segment remained largely pre-commercial as of July 2026. Merck and Daiichi Sankyo reported that no B7-H3-directed cancer medicine was approved when the U.S. Food and Drug Administration accepted the application for ifinatamab deruxtecan in April 2026. MediLink Therapeutics has since moved tam-Peli, also known as YL201, into formal regulatory review in China, but an accepted application is not an approval. Current market revenue therefore comes mainly from research antibodies, custom antibody development, biomarker testing, clinical research services, licensing payments, and development-related manufacturing. Commercial therapeutic sales could become the largest revenue pool if late-stage ADC programs secure approvals.

 

Broad Tumor Expression Expands the Addressable Application Base

CD276 is a cell-surface protein found at elevated levels in several solid tumors and in parts of the surrounding tumor tissue. Its expression has been reported in small cell lung cancer, prostate cancer, non-small cell lung cancer, breast cancer, nasopharyngeal carcinoma, head and neck cancer, brain tumors, and other malignancies. Higher B7-H3 expression has also been associated with tumor progression and poorer outcomes in several cancer types.

This expression pattern allows developers to test the same target across multiple cancer populations. A successful product in one tumor can be expanded into additional indications without rebuilding the entire targeting platform. Revenue potential can therefore extend beyond an initial orphan or later-line setting into larger patient groups, combination regimens, and earlier treatment lines.

B7-H3 is also expressed on tumor-associated stroma and blood vessels, which may allow a targeted product to affect both malignant cells and their supporting environment. Preclinical research published in 2023 found widespread CD276 expression across cancer cells and tumor-associated tissue and showed that antibody engineering could improve the therapeutic index of a B7-H3 ADC.

Broad expression does not guarantee broad adoption. Developers still need to establish whether tumor testing can predict response and how much B7-H3 expression is required. These questions influence trial design, eligible patient numbers, and companion-diagnostic demand.

 

ADCs Have Become the Main Pharmaceutical Growth Segment

Earlier CD276 programs included conventional monoclonal antibodies, radiolabeled antibodies, bispecific constructs, and immune-cell therapies. These approaches demonstrated that B7-H3 could be reached therapeutically, but they did not establish a broadly approved commercial class.

ADCs have moved ahead because they use an antibody to deliver a cancer-killing payload toward B7-H3-expressing cells. Their commercial value depends on the combined performance of the antibody, linker, payload, manufacturing process, dosing schedule, and safety profile. The leading programs largely use topoisomerase I inhibitor payloads, creating a closely contested product segment in which response duration, survival, lung toxicity, hematologic toxicity, dosing convenience, and activity in brain metastases may matter more than target novelty.

Pipeline concentration around ADCs is also expanding demand for antibody discovery, conjugation, linker-payload production, biomarker services, clinical-trial support, and commercial-scale biologics manufacturing. Revenue is therefore distributed across licensors, pharmaceutical companies, contract manufacturers, research-antibody suppliers, laboratories, and CROs.

Ifinatamab deruxtecan, or I-DXd, is one of the most advanced products in this segment. The FDA accepted its Biologics License Application and granted Priority Review in April 2026 for adults with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. The regulatory action date is October 10, 2026, and the application is being reviewed through the FDA’s Real-Time Oncology Review and Project Orbis programs.

The application is supported primarily by the Phase II IDeate-Lung01 study. At the selected 12 mg/kg dose, the confirmed objective response rate was 48.2%, median response duration was 5.3 months, and median progression-free survival was 4.9 months. The estimated overall survival rate at nine months was 59.1%. These findings established clinically meaningful activity in a population with limited options after platinum treatment.

Small cell lung cancer provides a focused initial application because the disease commonly returns after first-line treatment and can progress quickly. Approximately 250,000 people are diagnosed with SCLC worldwide each year, while about 27,000 new U.S. cases were estimated for 2025, according to the companies developing I-DXd. Daiichi Sankyo and Merck are also evaluating the product in Phase III studies covering SCLC, castration-resistant prostate cancer, and esophageal squamous cell carcinoma. Successful label expansion would broaden revenue beyond the initial lung-cancer population.

GSK and Hansoh Pharma are developing risvutatug rezetecan, or Ris-Rez, previously known as HS-20093 or GSK5764227. The product has received regulatory designations in relapsed or refractory extensive-stage SCLC, osteosarcoma, and other settings. In July 2026, Hansoh reported that the China-based Phase III ARTEMIS-008 trial met its primary overall survival endpoint. Ris-Rez produced a statistically significant and clinically meaningful survival improvement over topotecan, together with a consistent progression-free survival benefit. GSK described it as the first positive Phase III overall survival result reported for a B7-H3-targeted ADC in any tumor type.

The result strengthens validation of the ADC segment but also raises competition in SCLC. If both products enter major markets, hospitals and payers will compare survival, response durability, toxicity, dosing, brain-metastasis evidence, and treatment cost. GSK expects pivotal data from the global Phase III EMBOLD SCLC-301 trial in 2027.

MediLink’s tam-Peli, or YL201, is creating another commercial route through nasopharyngeal carcinoma. In July 2026, China’s National Medical Products Administration accepted its New Drug Application for adults with recurrent or metastatic disease who had failed a PD-(L)1 inhibitor and at least two chemotherapy lines. The submission is based on the randomized Phase III TAISHAN-301 study, which met its objective response rate co-primary endpoint.

China is especially important for this application. MediLink cited approximately 51,000 new nasopharyngeal carcinoma cases and 28,000 deaths in China in 2022, representing about half of global incidence and more than one-third of worldwide deaths. This concentration gives Chinese developers a strong domestic recruitment base and a commercially relevant launch population.

Earlier Phase I and Phase Ib findings across 312 patients reported objective response rates of 63.9% in SCLC, 48.6% in nasopharyngeal carcinoma, 28.6% in lung adenocarcinoma, and 54.2% in pulmonary lymphoepithelioma-like carcinoma. These results came from early-stage, non-randomized cohorts and should not be treated as direct comparisons with competing products.

 

Licensing Activity Places Strategic Value Ahead of Drug Sales

Large pharmaceutical companies are paying substantial amounts to secure B7-H3 assets before approval. These transactions show that industry valuation is based on future multi-indication oncology franchises rather than current therapeutic revenue.

GSK licensed ex-China rights to HS-20093 from Hansoh Pharma in 2023. Hansoh received USD 185 million upfront and became eligible for up to USD 1.525 billion in development, regulatory, and commercial milestones, in addition to royalties.

Roche entered an exclusive agreement for YL201 outside mainland China, Hong Kong, and Macau in January 2026. MediLink disclosed USD 570 million in upfront and near-term milestone payments, with further development, regulatory, and commercial milestones and sales royalties available.

Merck’s 2023 collaboration with Daiichi Sankyo covered three ADCs, including I-DXd. The portfolio agreement included USD 4 billion in upfront payments, USD 1.5 billion in continuation payments, and as much as USD 16.5 billion in additional sales milestones, for a potential combined value of up to USD 22 billion. The full value cannot be assigned to CD276 because the agreement also covered ADCs directed at other targets.)

BioNTech and DualityBio agreed to develop two ADC candidates, including the B7-H3 program BNT324/DB-1311, for USD 170 million upfront and more than USD 1.5 billion in possible milestone payments. BNT324 later received FDA Fast Track Designation for advanced metastatic castration-resistant prostate cancer.

These agreements give smaller biotechnology companies access to global trials, manufacturing, regulatory expertise, and oncology sales infrastructure. Licensing revenue and milestone income will remain important until approved-product sales become established.

 

Research Antibodies Maintain the Existing Revenue Base

Research-use CD276 antibodies are already sold for immunohistochemistry, flow cytometry, Western blotting, imaging, cell characterization, and drug-development studies. They support target-expression research, patient-sample analysis, assay development, preclinical screening, and translational biomarker work.

Thermo Fisher Scientific’s catalog lists 87 B7-H3/CD276 antibodies, including monoclonal products intended for research use and tissue staining. BD Biosciences markets human CD276 antibodies for flow cytometry and immunohistochemistry, while BioLegend offers conjugated and purified formats for cell analysis. Bio-Rad supplies clone RM335 for paraffin-embedded tissue testing, Western blotting, and related research applications.

This product segment is smaller than the potential therapeutic opportunity but benefits from a broader end-user base and lower development risk. Each new clinical program can increase demand for validated clones, staining protocols, reference materials, flow cytometry reagents, and custom assay services.

Suppliers compete through clone specificity, lot consistency, validation data, conjugate availability, and delivery reliability. Pharmaceutical developers need reproducible results across laboratories and clinical sample testing, making quality documentation commercially important.

 

Safety and Biomarker Performance Will Shape Market Share

B7-H3 ADCs should not be presented as free from systemic toxicity. Their targeted design may reduce some non-selective exposure, but the attached payload can still cause clinically important adverse events.

In IDeate-Lung01, 36.5% of patients receiving the selected 12 mg/kg I-DXd dose experienced grade 3 or higher treatment-related adverse events. Frequently reported events included nausea, anemia, and neutropenia. Treatment-related interstitial lung disease occurred in 12.4% of patients, including grade 3 or higher cases in 4.4%.

In the early YL201 study, grade 3 or higher neutropenia occurred in 31.7% of patients, leukopenia in 29.5%, and anemia in 25.0%. Interstitial lung disease was reported in 1.3%. Differences in patient populations, follow-up, dosing, and assessment prevent direct cross-trial comparisons, but hematologic toxicity and lung safety are likely to influence treatment duration, hospital monitoring, prescribing confidence, and eventual product market share.

Earlier radiolabeled antibody programs such as intraventricular omburtamab produced a different safety pattern. Reported acute effects included headache, vomiting, and fever, while rare grade 3 events included chemical meningitis and worsening communicating hydrocephalus. These effects reflect the specialized route of administration rather than the expected safety profile of systemic ADCs.

Biomarker strategy remains unresolved. The YL201 Phase I analysis did not find a significant relationship between measured B7-H3 membrane expression and objective response. This could support broad treatment eligibility without mandatory testing, but it may also indicate that current assays do not fully capture target accessibility, expression across metastatic sites, or payload sensitivity.

Pharmaceutical companies and diagnostic laboratories will continue investing in immunohistochemistry assays, digital pathology, circulating biomarkers, and retrospective tissue analysis. A predictive test could improve treatment selection but reduce the eligible population. The absence of a mandatory companion diagnostic would simplify prescribing while increasing the risk of treating patients unlikely to respond.

CD276-directed CAR T-cell therapy and radioimmunotherapy remain smaller product niches. Interim findings from a recurrent-glioblastoma study reported no dose-limiting toxicities among nine evaluable patients, mild cytokine release syndrome in two patients, no moderate or severe cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and two partial responses.

Cell therapy may remain concentrated in specialist centers because of patient-specific manufacturing, CNS delivery, and toxicity monitoring. Radioimmunotherapy can serve selected pediatric and CNS tumors but depends on nuclear medicine infrastructure.

 

Regional Competition

North America is positioned as a major commercial region because of its oncology research infrastructure, high biologics spending, active FDA review pathways, and concentration of pharmaceutical and biotechnology companies. The U.S. Priority Review of I-DXd could establish the first major pricing, reimbursement, and clinical-use benchmark for B7-H3 ADCs.

Asia Pacific has become central to clinical development and licensing. China contributes large patient pools in SCLC, nasopharyngeal carcinoma, and esophageal cancer and has produced several leading assets through Hansoh Pharma, MediLink Therapeutics, and DualityBio. The region is not only a trial-recruitment base; it is also an origin point for globally licensed antibody platforms.

Europe remains important through EMA pathways, multinational trials, oncology manufacturing, and established reimbursement systems. Latin America, the Middle East, and Africa represent smaller near-term opportunities because access to complex biologics and specialist centers remains limited.

 

Market Outlook Through 2032

At a 15.8% CAGR, the Global CD276 Antibody Market is projected to rise from USD 450 million in 2025 to USD 1.26 billion by 2032. ADCs are expected to become the principal therapeutic product segment if regulatory reviews convert into approvals, while research-use antibodies will continue supplying recurring revenue across pharmaceutical companies, CROs, academic institutes, hospitals, and pathology laboratories.

Small cell lung cancer is likely to become the first major commercial battleground. Nasopharyngeal carcinoma provides an important China-led entry point, while prostate cancer, esophageal cancer, osteosarcoma, glioblastoma, and gynecological cancers offer longer-term expansion opportunities.

Not every program will reach the market. MacroGenics discontinued further development of vobramitamab duocarmazine while continuing work on another B7-H3 ADC, MGC026. The decision illustrates how payload choice, efficacy, safety, financing, and portfolio priorities can separate target validation from product success.

Companies with late-stage survival evidence, manageable lung and blood-related toxicity, scalable manufacturing, broad geographic rights, and credible label-expansion plans are likely to secure the strongest positions. Research-antibody suppliers can benefit from increasing trial activity regardless of which therapeutic asset succeeds, while biotechnology licensors can generate value through upfront payments, milestones, and royalties.

By 2032, the market could contain several approved B7-H3 ADCs differentiated by tumor indication, treatment line, safety profile, dosing schedule, and regional rights. The commercial structure is therefore likely to include a portfolio of therapeutic antibodies supported by research reagents, biomarker testing, clinical-development services, manufacturing partnerships, and long-term licensing income.

 

CD276 Antibody Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 450 Million
Revenue Forecast in 2032	USD 1.26 Billion
Overall Growth Rate	CAGR of 15.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Type, By Application, By End User, By Geography
By Type	Monoclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies
By Application	Oncology, Immuno-Oncology Research
By End User	Biopharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for targeted oncology therapies, advancement of B7-H3 antibody-drug conjugates, increasing solid tumor research activity, growth in precision oncology programs, expanding biomarker-driven clinical trials, and strategic licensing collaborations among biotechnology and pharmaceutical companies
Customization Option	Available upon request